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critical to arresting renal ﬁbrosis, the 
major determinant of progressive renal 
failure. GW788388, a new TGF-β type 
I receptor inhibitor, has an improved 
pharmacokinetic proﬁle compared with 
previous agents and can be administered 
orally. Petersen et al. studied its eﬀect 
on diabetic nephropathy in the db/db 
mouse model. They found that, in vitro, 
GW788388 appeared to be speciﬁc to 
the type I and type II receptor kinases. 
Further, it blocked the downstream 
eﬀect of receptor activation on Smad 
gene activation and its target recep-
tor genes. In the db/db mice, which 
develop nephropathy similar to human 
diabetic renal disease, 5-week treatment 
reduced renal ﬁbrosis and decreased the 
expression levels of many mediators of 
renal ﬁbrosis. One type of mediator is 
extracellular matrix proteins, which 
get deposited in the kidney and are 
targets of the activity of TGF-β. These 
promising in vivo preclinical trials are 
an important pathway in renal disease. 
See page 705.
Blood pressure control 
during dialysis
The control of blood pressure in end-
stage renal disease is an important 
therapeutic goal, as cardiovascular events 
are the leading causes of mortality in this 
population. A number of organizations 
introduced target blood pressure levels to 
aid clinicians in developing proper ﬂuid 
removal strategies for individual patients. 
In a new study, Davenport et al. audited 
the treatment of several thousand patients 
at renal centers in London, England, for 
one week. Only a third of the patients 
achieved predialysis blood pressure 
targets, while 42% achieved postdialy-
sis blood pressure targets. The use of 
diﬀerent antihypertensive medications 
did not correlate with blood pressure 
levels. However, 15% of the patients suf-
fered from symptomatic hypotension, 
which required ﬂuid resuscitation and 
was associated with signiﬁcantly greater 
interdialytic weight gain. Intradialytic 
hypotension was signiﬁcantly greater in 
centers that achieved better postdialysis 
blood pressure targeting. Although gen-
eral recommendations only work on the 
average patient, these results suggest that 
blood pressure control recommendations 
in dialysis patients might be useful. See 
page 759.
Oral TGF-β blockade 
in mouse diabetic 
nephropathy
Overwhelming evidence now exists 
that renal injury leads to overexpres-
sion of transforming growth factor-β 
(TGF-β), the major mediator of renal 
ﬁbrosis. Hence, development of agents 
that interfere with this pathway is 
A new biomarker?
Although identification of new bio-
markers is not a new ﬁeld, the discovery 
of new molecules is increasing. Allory et 
al. now present evidence that the L1 cell 
adhesion molecule (CD171) is a poten-
tial new biomarker for tubular injury. 
It is expressed in human acute kidney 
injury and excreted in the urine, impor-
tant characteristics of a good biomarker. 
L1 is located in the basolateral membrane 
in all epithelial cells of the collecting duct 
in the normal kidney except for interca-
lated cells. In acute tubular necrosis, L1 
lost its polarized distribution and was 
also induced in the thick ascending limb 
and distal tubule cells. In the study, levels 
of urinary L1, normalized for creatinine, 
were signiﬁcantly higher in the 24 patients 
with acute tubular necrosis compared 
with ﬁve patients with prerenal azotemia 
and six patients with other causes of acute 
kidney injury. The ideal biomarker is one 
whose ﬁnding informs the clinician of the 
pathophysiology in the same way that a 
pregnancy test (the ultimate biomarker) 
is definitive because it measures the 
excretion of the hormone that causes preg-
nancy. One exciting aspect of the search 
for biomarkers is that it might uncover 
new and unexpected pathophysiological 
mechanisms. See page 751.
